Nuvectis Pharma (NVCT) Share-based Compensation (2021 - 2026)

Nuvectis Pharma has reported Share-based Compensation for 6 years, with the latest figure at $8.5 million in Q1 2026.

• Quarterly Share-based Compensation rose 521.35% year-over-year to $8.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.5 million (up 94.6% YoY) and the FY2025 annual result came in at $6.0 million, up 24.17% from the prior year.
• Share-based Compensation improved to $8.5 million in Q1 2026 per NVCT's latest filing, from $1.5 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $8.5 million in Q1 2026 and troughed at $156000.0 in Q1 2022.
• A 5-year average of $1.6 million and a median of $1.1 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation sank 66.67% in 2022, then surged 798.72% in 2023.
• Over 5 years, Share-based Compensation stood at $482000.0 in 2022, then jumped by 153.11% to $1.2 million in 2023, then retreated by 6.48% to $1.1 million in 2024, then rose by 29.36% to $1.5 million in 2025, then soared by 475.88% to $8.5 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $8.5 million, $1.5 million, and $900000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.